SINGAPORE, Dec. 29, 2025 — EUDA Health Holdings Limited (NASDAQ: EUDA) — also known as “EUDA” or “the Company” — a Singapore-headquartered non-invasive healthcare provider operating in Asia with a focus on Singapore, Malaysia, and China, today announced plans to launch EUDA Helixé 2.0 in January 2026. This marks the next-generation upgrade of its premium supplement for youthful vitality and longevity. EUDA Helixé 2.0 includes enhancements across formulation potency, ingredient technology, delivery systems, packaging design, and global market readiness.
Enhanced Formula and Ingredient Tuning
EUDA Helixé 2.0 features a 20% increase in New Zealand-sourced deer placenta powder, with the dosage raised from 100 mg to 120 mg — reinforcing the supplement’s position as a high-potency vitality formula. As part of the formulation upgrade, L-glutathione has been replaced with D-alpha-tocopherol (1.4 mg Vitamin E equivalent). This change is designed to boost antioxidant stability, support cellular protection, improve skin health, and enhance overall youthful vigor, aligning EUDA Helixé 2.0 with long-term wellness and anti-aging goals.
Cutting-Edge Encapsulation and Preservation Technology
EUDA Helixé 2.0 leverages an upgraded ingredient preservation and delivery platform built to enhance stability, absorption efficiency, and shelf life:
- Freeze Drying: Powdered ingredients undergo freeze-drying to retain nutrient potency while removing moisture without altering their molecular properties.
- Refining Technology: Oil-based ingredients are refined to improve stability, reduce allergenic and reactive potential, and increase resistance to heat and light.
- Nitrogen Encapsulation: Nitrogen protection minimizes oxidation and hydrolysis, extending the product’s shelf life.
- Nano Emulsification (Replaced Enteric Coating): The nano-sized formulation enhances solubility, bioavailability, and absorption speed, enabling more efficient nutrient delivery than a traditional enteric coating.
This nano-based delivery system allows EUDA Helixé 2.0 to have a smaller capsule size, designed to improve user experience through efficient nutrient absorption while maintaining or enhancing functional efficacy.
New Exclusive Bottle Design
Alongside the product upgrade, EUDA is introducing a new proprietary EUDA Helixé bottle design that reflects the supplement’s premium positioning while enhancing product protection, shelf presence, and brand identity.
New Zealand Halal Certification and Global Market Expansion
EUDA Helixé 2.0 has secured New Zealand Halal certification, enabling broader international distribution and formal entry into Muslim markets across Southeast Asia, the Middle East, and other global regions.
Positioning EUDA Helixé for Global Growth
The upcoming January 2026 launch of EUDA Helixé 2.0 underscores EUDA Health’s commitment to continuous innovation, scientific advancement, and scalable global wellness solutions. With enhanced formulation strength, advanced delivery technology, refined packaging, and expanded market accessibility, EUDA Helixé 2.0 is positioned as a core offering within EUDA’s growing health and longevity ecosystem.
Mr Alfred Lim, CEO of EUDA, commented:
“This marks an important milestone in EUDA’s product evolution. With EUDA Helixé 2.0, we are strengthening our core formulation, upgrading delivery technology, and expanding global market accessibility through Halal certification. These enhancements reflect our commitment to science-backed innovation and position EUDA Helixé as a premium longevity supplement aligned with EUDA’s broader strategy to scale high-quality wellness solutions globally.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region, which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements typically use forward-looking words such as “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors — many of which are outside EUDA’s control — that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements, which are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail:
